Cargando…

Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia

INTRODUCTION: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for the management of non-severe ABSSSIs from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcellusi, Andrea, Bini, Chiara, Rotundo, Maria A, Cultrera, Rosario, Mennini, Francesco S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677603/
https://www.ncbi.nlm.nih.gov/pubmed/36627961
http://dx.doi.org/10.33393/grhta.2020.2138
_version_ 1784833840451158016
author Marcellusi, Andrea
Bini, Chiara
Rotundo, Maria A
Cultrera, Rosario
Mennini, Francesco S
author_facet Marcellusi, Andrea
Bini, Chiara
Rotundo, Maria A
Cultrera, Rosario
Mennini, Francesco S
author_sort Marcellusi, Andrea
collection PubMed
description INTRODUCTION: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for the management of non-severe ABSSSIs from the National Health Service (NHS) perspective. METHODS: A probabilistic decision tree model was developed considering a 30-days follow-up to simulate the therapeutic pathway of a patient treated with dalbavancin or Standard of Care (SoC). The model considered three mutually exclusive health states: a) discharge of patients from the emergency department, b) discharge of patients after one night from admission, c) discharge after 24 or 36 hours from admission. A one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis were conducted. RESULTS: The analysis showed that the use of dalbavancin in patients with non-severe ABSSSI compared to SoC could generate a reduction in costs (– € 291.6 per patient treated) and an increase in QALYs (+0.0018 per patient treated). In 99.7% of the simulations carried out, dalbavancin was dominant compared to the SoC. Considering a threshold for the willingness to pay of € 30,000 for QALY gained, the minimum level of efficacy of dalbavancin so that the treatment can be considered cost-effective compared to the SoC was equal to 69.4%. CONCLUSIONS: The analysis showed that dalbavancin may represent a cost-effective option compared to SoC for the treatment of patients with non-severe ABSSSI.
format Online
Article
Text
id pubmed-9677603
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AboutScience
record_format MEDLINE/PubMed
spelling pubmed-96776032023-01-09 Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia Marcellusi, Andrea Bini, Chiara Rotundo, Maria A Cultrera, Rosario Mennini, Francesco S Glob Reg Health Technol Assess Original Research Article INTRODUCTION: Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) include all complicated skin and soft tissue infections. The aim of this study was to conduct a cost-utility analysis to compare dalbavancin with standard antibiotic therapies for the management of non-severe ABSSSIs from the National Health Service (NHS) perspective. METHODS: A probabilistic decision tree model was developed considering a 30-days follow-up to simulate the therapeutic pathway of a patient treated with dalbavancin or Standard of Care (SoC). The model considered three mutually exclusive health states: a) discharge of patients from the emergency department, b) discharge of patients after one night from admission, c) discharge after 24 or 36 hours from admission. A one-way deterministic sensitivity analysis and a probabilistic sensitivity analysis were conducted. RESULTS: The analysis showed that the use of dalbavancin in patients with non-severe ABSSSI compared to SoC could generate a reduction in costs (– € 291.6 per patient treated) and an increase in QALYs (+0.0018 per patient treated). In 99.7% of the simulations carried out, dalbavancin was dominant compared to the SoC. Considering a threshold for the willingness to pay of € 30,000 for QALY gained, the minimum level of efficacy of dalbavancin so that the treatment can be considered cost-effective compared to the SoC was equal to 69.4%. CONCLUSIONS: The analysis showed that dalbavancin may represent a cost-effective option compared to SoC for the treatment of patients with non-severe ABSSSI. AboutScience 2020-11-06 /pmc/articles/PMC9677603/ /pubmed/36627961 http://dx.doi.org/10.33393/grhta.2020.2138 Text en Copyright © 2020, The Authors https://creativecommons.org/licenses/by-nc/4.0/Global & Regional Health Technology Assessment - ISSN 2283-5733 - www.aboutscience.eu/grhta (http://www.aboutscience.eu/grhta) © 2020 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu (http://www.aboutscience.eu)
spellingShingle Original Research Article
Marcellusi, Andrea
Bini, Chiara
Rotundo, Maria A
Cultrera, Rosario
Mennini, Francesco S
Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title_full Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title_fullStr Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title_full_unstemmed Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title_short Costo-utilità di dalbavancina versus standard of care (SoC) in pazienti con ABSSSI non severa in Italia
title_sort costo-utilità di dalbavancina versus standard of care (soc) in pazienti con absssi non severa in italia
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677603/
https://www.ncbi.nlm.nih.gov/pubmed/36627961
http://dx.doi.org/10.33393/grhta.2020.2138
work_keys_str_mv AT marcellusiandrea costoutilitadidalbavancinaversusstandardofcaresocinpazienticonabsssinonseverainitalia
AT binichiara costoutilitadidalbavancinaversusstandardofcaresocinpazienticonabsssinonseverainitalia
AT rotundomariaa costoutilitadidalbavancinaversusstandardofcaresocinpazienticonabsssinonseverainitalia
AT cultrerarosario costoutilitadidalbavancinaversusstandardofcaresocinpazienticonabsssinonseverainitalia
AT menninifrancescos costoutilitadidalbavancinaversusstandardofcaresocinpazienticonabsssinonseverainitalia